Photo by lamoune from unsplash
Due to the outbreak of the coronavirus disease 2019 (COVID19) pandemic, clinical trial (CT) research for efficacy and safety evaluation of convalescent plasma (CP) accelerated globally. In trial planning and… Click to show full abstract
Due to the outbreak of the coronavirus disease 2019 (COVID19) pandemic, clinical trial (CT) research for efficacy and safety evaluation of convalescent plasma (CP) accelerated globally. In trial planning and approval, clinical researcher and regulatory agencies worldwide are challenged by limited evidence from the use of convalescent plasma in previous outbreaks of viral diseases and by different possible study approaches. We analyzed CT designs to identify potential opportunities for data aggregation and to facilitate generation of decisionrelevant evidence.
Journal Title: Clinical Pharmacology and Therapeutics
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!